Clay Thorp Chairman
Clay co-founded PhaseBio Pharmaceuticals in 2002 and has served as a member of the company’s board of directors since that time. He has served as Chairman of PhaseBio since November 2014. Since 1995, Clay has co-founded seven life sciences companies, including PhaseBio. He also co-founded Hatteras Venture Partners in 2000, where he has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $350 million across five funds. Clay was co-founder, CEO and Chairman of Synthematix, Inc., a chemistry informatics company acquired in April 2005 by Symyx Technologies. He was the co-founder and Head of Corporate Development for Novalon Pharmaceutical Corporation, where he led financing efforts and was Head of Business Development from inception until Novalon’s sale to Karo Bio for $106.7 million in May 2000. Prior to Novalon, Clay was the co-founder and President of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Clay currently serves as Chairman of GeneCentric Diagnostics and on the boards of Clearside Biomedical, Curoverse, Lysosomal Therapeutics and Orig3n. He received a BA in mathematics and art history from the University of North Carolina at Chapel Hill and a Masters of Public Policy from Harvard University.
Richard van den Broek
Rich has served as a member of PhaseBio’s board of directors since February 2019. He has nearly 30 years of experience in financial strategy and investment fund management in the life sciences industry, and currently serves as managing partner of HSMR Advisors, an investment fund focused on the biotechnology industry. Prior to joining HSMR Advisors in 2004, Rich was partner at Cooper Hill Partners. Earlier in his career, he was a biotechnology analyst at Hambrecht & Quist, Merrill Lynch and Oppenheimer, and has previously served as a director at Pharmacyclics, Response Genetics and Celldex Therapeutics. Rich holds a bachelor’s degree from Harvard University and is a Chartered Financial Analyst.
Edmund Harrigan, MD
Ed has served as a member of PhaseBio’s board of directors since December 2018. He has nearly 30 years of pharmaceutical industry experience, serving in various executive leadership positions across business development, clinical development, drug safety, and regulatory affairs. Ed spent 18 years at Pfizer, most recently as Senior Vice President of Worldwide Safety and Regulatory. Previously, Ed served as President and CEO of Karuna Pharmaceuticals, and in senior clinical leadership positions at Neurogen and Sepracor. Prior to entering the pharmaceutical industry, Ed was a practicing neurologist for seven years. He currently serves on the boards of directors of Karuna Pharmaceuticals, ACADIA Pharmaceuticals, and Lyndra Therapeutics. Ed holds a BA in chemistry from Saint Anselm College and an MD from the University of Massachusetts Medical School.
Nancy Hutson, PhD
Nancy has served as a member of PhaseBio’s board of directors since March 2018. She has more than 30 years of experience in the pharmaceutical industry. She retired from Pfizer Inc. in 2006 after spending 25 years in research and leadership positions, most recently serving as Senior Vice President of Global Research & Development and director of Pfizer’s pharmaceutical research and development site Groton / New London Laboratories. Nancy currently serves on the boards of directors for BioCryst Pharmaceuticals, Inc. and Endo International plc. She received a BA in general biology from Illinois Wesleyan University and a PhD in physiology and biochemistry from Vanderbilt University.
Justin Klein, MD, JD
Justin has served as a member of PhaseBio’s board of directors since December 2009. He is a healthcare-focused venture capital investor, and previously served as a partner at New Enterprise Associates. He is a member of the boards of directors of multiple emerging growth companies, including Senseonics Holdings. Previously, Justin worked for the Duke University Health System, reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations. Justin received an AB in economics and a BS in biological anthropology and anatomy from Duke University, an MD from the Duke University School of Medicine and a JD from Harvard Law School.
Caroline has served as a member of PhaseBio’s board of directors since July 2018. She is a consultant providing strategy advisory services for biopharmaceutical companies and has more than 25 years of experience in the biotechnology industry. She has held numerous executive roles, most recently as co-founder, Chief Financial Officer and Chief Business Officer of Achieve Life Sciences, Inc. (acquired by OncoGenex). Earlier in her career, Caroline served as Chief Financial Officer of Tobira Therapeutics, Inc., Corcept Therapeutics, Inc. and Poniard Pharmaceuticals, Inc. Caroline serves on the boards of directors of Aptose Biosciences, Inc. and CymaBay Therapeutics, Inc. She is a founding board member of the Global Genes Project, a leading rare disease patient advocacy organization, a member of the National Advisory Committee of the Translational Genomics Research Institute’s Center for Rare Childhood Disorders and a co-founder of KCNQ2 Cure Alliance, a non-profit advancing research for the rare disease KCNQ2 epileptic encephalopathy. Caroline received a BA from the University of California, Berkeley and an MBA and MS from Carnegie Mellon University.
Jonathan is a life sciences executive with more than 25 years of experience in biotechnology management. He previously served as Chief Business Officer of PhaseBio. Prior to PhaseBio, Jonathan served as Vice President, Business Development for Amylin Pharmaceuticals from 2007 until its sale to Bristol-Myers Squibb in 2012. Jonathan was co-founder and Vice President, Commercial and Business Development of Corus Pharma, Inc., until its acquisition by Gilead Sciences in 2006. Earlier in his career, he led the business development efforts for PathoGenesis Corporation, culminating in the company’s acquisition by Chiron Corporation in 2000. Jonathan has held positions in sales and marketing at Bristol-Myers Squibb, Wyeth / Lederle International and Syntex Laboratories. Jonathan received a BS in Mechanical Engineering from the University of California, Berkeley and an MBA from the Carnegie Mellon University Tepper School of Business.
Bibhash Mukhopadhyay, PhD
Bibhash has served as a member of PhaseBio’s board of directors since February 2018. He is a principal at New Enterprise Associates, Inc., where he focuses on investing in emerging therapeutic and device companies, helping them grow and create value. Previously, he was Associate Director of Business Development at MedImmune, a subsidiary of AstraZeneca, and held multiple business development positions at Johnson & Johnson. Bibhash received a BS in biochemistry and molecular biology from the All India Institute of Medical Sciences, New Delhi, an MS in neuroscience from Georg-August-Universität, Göttingen and a PhD in biomedical sciences from Baylor College of Medicine.
Linda has served as a member of PhaseBio’s board of directors since March 2018. She has more than 35 years of experience working with companies across healthcare and life sciences and currently serves as a general partner at Fletcher Spaght Ventures and Fletcher Spaght, Inc., a Boston-based consultancy focused on growth strategies for healthcare and IT clients. Prior to Fletcher Spaght, she held positions at the Sony Corporation of America and Bain & Company. Linda currently serves on the boards of directors at Juventas Therapeutics and HistoSonics. She received an SB in electrical engineering and computer science and an SB in humanities and science from the Massachusetts Institute of Technology, and an SM in management (finance) from the Sloan School of Management at the Massachusetts Institute of Technology.